2020•Journal of the American Academy of DermatologyRequires access

14161 Ixekizumab is superior to placebo for the treatment of nail, scalp, and palmoplantar psoriasis in pediatric patients with moderate to severe plaque psoriasis

Amy S. Paller, Gabriel A. Magariños, Andreas Pinter, Jennifer Cather, Stuart Keller, Claudia Rodriguez Capriles, Gaia Gallo, Emily Edson‐Heredia, Lingnan Li, Kim Papp

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ixekizumab, Medicine, Psoriasis, Dermatology, Plaque psoriasis, Scalp, Placebo, Nail (fastener)